Mirae (Mirae Health), a developer of a new conversational AI copilot that turns everyday patient input into structured, longitudinal insight, enabling earlier intervention and more informed treatment decisions, raised $5.4 million in a new funding round led by Oxford Science Enterprises.
Mirae conversational AI copilot captures what patients experience between visits and converts it into a continuous, structured view of disease that clinicians can act on at the point of care, combining patient-reported data with clinical context and peer-reviewed evidence to support more informed, timely treatment decisions.
The New York-based startup Mirae is initially focused on inflammatory bowel disease (IBD), a condition marked by unpredictable flares, complex medication decisions, and highly variable treatment responses.
Mirae is already deployed by a leading U.S. health system, providing ongoing access to real-world patient data to support model development and validation.
Commenting on the fundraise, Anuj Patel, co-founder and CEO of Mirae, said: “The limitations of AI in understanding and modeling complex disease come from the fact that patients are living with their disease every day, but that experience rarely makes it into the clinical record in a usable way. When you combine experiential data with clinical data, you begin to understand and model disease more effectively and have a path towards true precision medicine. Every patient deserves access to world-class decision-making for their care and the tools to take ownership over their condition between visits.”
Commenting on the investment, Joel Schoppig, Health Tech Principal, Oxford Science Enterprises, said: “AI is moving quickly into healthcare, but much of that activity remains broad, generalized, and disconnected from the clinical decisions that determine outcomes. Its greatest impact will come from areas where decisions are complex, conditions evolve, and the cost of getting those decisions wrong is high.”
“Mirae is building for this deeper layer of medicine, where patient context, clinical evidence, and workflow need to come together to support a higher standard of care,” added Joel Schoppig.